Clinical management of uterine sarcomas
- 1 December 2009
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 10 (12), 1188-1198
- https://doi.org/10.1016/s1470-2045(09)70226-8
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- Genetic aberrations in soft tissue leiomyosarcomaCancer Letters, 2009
- Endometrial stromal sarcoma: a population-based analysisBritish Journal of Cancer, 2008
- Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenograftsMolecular Cancer Therapeutics, 2008
- Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trialGynecologic Oncology, 2008
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II studyGynecologic Oncology, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008
- Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcomaBritish Journal of Cancer, 2007
- Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyGynecologic Oncology, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002